# Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate

> **NCT00321763** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 3124 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Candidate Influenza Vaccine GSK1247446A - 3 different formulations
- **BIOLOGICAL:** Fluarix TM

## Key facts

- **NCT ID:** NCT00321763
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04-27
- **Primary completion:** 2006-07-01
- **Final completion:** 2006-07-07
- **Target enrollment:** 3124 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00321763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00321763, "Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00321763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*